A Cost-Utility Analysis of the Risk Model-Guided Antiemetic Prophylaxis Versus Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer- A Net-Benefit Regression Approach
Nov 1, 2016, 00:00
10.1016/j.jval.2016.08.744
https://www.valueinhealthjournal.com/article/S1098-3015(16)33859-1/fulltext
Title :
A Cost-Utility Analysis of the Risk Model-Guided Antiemetic Prophylaxis Versus Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer- A Net-Benefit Regression Approach
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33859-1&doi=10.1016/j.jval.2016.08.744
First page :
A890
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2742